- Stratification strategies for immune-targeted pharmacological treatments in Major Depressive Disorder

Livia De Picker,Céline Wessa,Benedetta Vai,Eimear Foley,Claudia Delli Colli
DOI: https://doi.org/10.1016/j.psyneuen.2023.106895
IF: 4.693
2024-02-01
Psychoneuroendocrinology
Abstract:Background Low-grade inflammation is present in 27% of patients with MDD and is associated with poor treatment outcomes of first-line antidepressants and a higher risk of chronicity. Baseline clinical and biological characteristics of low-grade inflammation may also predict treatment response to add-on pharmacological agents targeting immune-metabolic pathways, but most randomised clinical trials did not stratify between these patient subgroups. Methods The clinical trials subgroup of the NSAS Challenge Workshop on Brain Immune interactions focused on reviewing the literature to retrospectively identify stratified effect sizes for patient subtypes in immunomodulatory pharmacological trials. We will apply a systematic multi-step search procedure, including all eligible articles published until 30th April 2023 on PubMed (MEDLINE), Embase, the Cochrane Library (CENTRAL), and Web of Science (Clarivate Analytics). The search aims to include all trials, in any language, that has evaluated the use of anti- inflammatory agents in monotherapy or as an add-on to treat MDD. We will add several stratification analyses to explore predictors of treatment response, and we will construct three symptom dimension composite scores as outcome measures. The protocol will be refined during the workshop and will be presented together with details of the planned stratified meta-analysis, results of the systematic search, and more detailed stratification strategy with composite scores. Hypothesis We hypothesise that the effect sizes will be largest in patients (women) with a high inflammation index, a high metabolic index, and a high somatic load. We hypothesise that the treatment effect of immunomodulatory treatments will be largest in the atypical symptom domain.
neurosciences,endocrinology & metabolism,psychiatry
What problem does this paper attempt to address?